Eledon Pharmaceuticals (ELDN) Shares Outstanding (Diluted Average) (2021 - 2026)

Eledon Pharmaceuticals (ELDN) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $112.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 45.77% year-over-year to $112.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.4 million (up 45.77% YoY), and the FY2025 full-year result was $81.8 million, up 68.58% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $112.4 million, up from $81.8 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $112.4 million in Q1 2026 and bottomed at $114508.0 in Q1 2024.
• The 5-year median for Shares Outstanding (Diluted Average) is $22.8 million (2023), against an average of $38.1 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) tumbled 99.52%; it then jumped 67280.5% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $14.3 million in 2022, then sank by 99.17% to $118268.0 in 2023, then surged by 40945.58% to $48.5 million in 2024, then soared by 68.58% to $81.8 million in 2025, then jumped by 37.38% to $112.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $112.4 million (Q1 2026), $81.8 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.

Peer Comparison